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severe reﬂux oesophagitis (RO), Los Angeles grades C or D
compared with standard adult doses of other proton pump
inhibitors (PPIs), i.e., generic lansoprazole 30 mg od, generic
omeprazole 20 mg od, pantoprazole 40 mg od, and rabeprazole
20 mg od. METHODS: A simple decision-tree model was
designed to evaluate the cost-effectiveness of esomeprazole over a
6-month time horizon from the perspective of the UK National
Health Service. Healing rate probabilities were extrapolated
from the results of a meta-analysis of 6 randomised, controlled
trials that compared esomeprazole with other PPIs in adults who
had endoscopically-conﬁrmed RO. Data from the IMS Disease
Analyser was used to estimate the average duration of a course of
PPI therapy prescribed to adolescents in the UK. Health state
valuations were estimated from a European study that used Time
Trade Off to obtain utilities scores from a sample of more than
1,000 patients with GORD symptoms. RESULTS: Esomeprazole
was a cost-effective treatment option for adolescents with
moderate or severe RO versus all other standard-dose PPIs.
For example, incremental cost-effectiveness ratios ranged from
£2,200/QALY (95% CI, £1,100/QALY to £5,600/QALY) and
£15,200/QALY (95% CI, £6,700 to >£80,000/QALY), when
esomeprazole was compared with pantoprazole (in adolescents
with severe RO) and generic lansoprazole (in adolescents with
moderate RO), respectively. The probability of esomeprazole
being cost-effective at a threshold of £30,000/QALY was greater
than 84% for all the analyses that were undertaken. CONCLU-
SION: Esomeprazole is a cost-effective treatment for adolescent
patients who are presumed to have moderate or severe reﬂux
oesophagitis.
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OBJECTIVES: Determine which new generation proton pump
inhibitor (PPI) is most cost-effective in the treatment of GERD
after omeprazole failure as well as their expected impact on
Spanish NHS budget. METHODS: A pharmacoeconomic deter-
ministic model was developed, based on data extracted from
literature, form an NHS perspective to compare esomeprazole
(ESO40 mg/d), lansoprazole (LANSO30 mg/d), pantoprazole
(PANTO40 mg/d) and rabeprazole (RABE20 mg/d) in patients
with GERD refractory to omeprazole (patients without remission
or remaining symptomatic after OME 20 mg/day 4 weeks). The
effectiveness measure was symptom free-days after 12 months
of treatment. The costs included were drugs and health care
utilization resources (diagnostic methods, physicians visits and
surgery), expressed as 2006 €. Moreover a budget impact model
was done to know the affordability of most cost-effective drug
utilization in a 1000 patients cohort. RESULTS: ESO provide
higher remission rates (238 days without symptoms) than the
other alternatives: LANSO-213 days; PANTO-203 days; RABE-
205 days. The annual cost by patient are: 652€-ESO, 703€-
LANSO, 734€-PANTO; 706€-RABE. The analysis indicates that
ESO being a dominant therapy in this case. The expected cost by
patient is 428.84€ (310 symptoms free-days), based on 2006
treatment patterns. Increasing the ESO utilization on 25, 50, 75
& 100%, instead of less effective and costly drugs, could produce
potential savings for the Spanish NHS: 720€, 1430€, 2000€ &
2860€, respectively; which would allow for the treatment of
more patients with the same budget: 1.68, 3.35, 4.69 and 6.71
additional patients, correspondingly. CONCLUSION: ESO is the
most cost-effective and efﬁcient PPI in the treatment of GERD
after omeprazole failure in Spain.
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OBJECTIVES: To assess the impact of constipation on opioid use
patterns, resource utilization, and costs in patients on opioid
therapy. METHODS: A retrospective study was conducted in
patients who initiated opioid therapy between 1/1/99 and 12/31/
05. Patients were identiﬁed from longitudinal insurance claims
from US health plans. An index date was deﬁned as the date of
the 1st pharmacy claim for an opioid. Patients had 30 days of
opioid use and continuous plan coverage for 6 months before
and 12 months after their index date. Outcomes were assessed
over 12 months following the index date. Constipation was
deﬁned as evidence of 1 ICD-9 code of 564.0 in the follow-up
period. Opioid use patterns were compared between patients
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